Gamida Cell - Cell and Immune Therapy Technologies

Latest News

View All

Dec 09, 2019

Gamida Cell Announces Results from Phase 1 Study of GDA-201 and New Mechanism of Action Data at ASH 2019 Annual Meeting

Gamida Cell to Present at the 31st Annual Piper Jaffray Healthcare Conference

Gamida Cell Reports Third Quarter 2019 Financial Results and Provides Company Update

Gamida Cell Announces Data to be Presented at ASH 2019 Annual Meeting

Gamida Cell Announces the Date of Its Third Quarter 2019 Financial Results and Webcast

Gamida Cell and the CIBMTR Announce Collaboration to Advance Research for Life-Saving Cellular Therapy

Gamida Cell Reports Second Quarter 2019 Financial Results and Provides Company Update

Gamida Cell Announces the Date of Its Second Quarter 2019 Financial Results and Webcast

Gamida Cell Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

Gamida Cell Announces Pricing of $35 Million Public Offering of Ordinary Shares

Gamida Cell Announces Launch of Proposed Public Offering of Ordinary Shares

Gamida Cell and Lonza Establish Commercial Manufacturing Agreement for Omidubicel

Gamida Cell Bolsters Management Team with Appointment of Tracey Lodie, Ph.D., as Chief Scientific Officer

Gamida Cell Announces Data for Omidubicel Presented at the International Society for Cellular and Gene Therapy 2019 Annual Meeting

Gamida Cell to Hold Annual Meeting of Stockholders

Gamida Cell to Participate in Two Upcoming Healthcare Conferences in New York City

Gamida Cell Reports First Quarter 2019 Financial Results and Provides Company Update

Gamida Cell Announces the Date of Its First Quarter 2019 Financial Results and Webcast

Gamida Cell to Present at the Solebury Trout Class of 2018 Biotech IPOs Investor Day

Gamida Cell to Present at the 18th Annual Needham Healthcare Conference

Gamida Cell Nominates Two Healthcare Industry Veterans to Its Board of Directors

Gamida Cell Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update

Gamida Cell Announces Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at 2019 TCT Annual Meeting

Gamida Cell Presents New Data from Ongoing Phase 1 Study of NAM-NK and Initial Data from Phase 1/2 Study of NiCord® in Severe Aplastic Anemia at 2019 TCT Annual Meeting

Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells

Gamida Cell to Host Conference Call and Webcast to Review Data from NAM-NK and NiCord® Programs Being Presented at 2019 TCT Annual Meeting

Gamida Cell Announces Data from NAM-NK and NiCord® Programs to Be Presented at 2019 TCT Annual Meeting

Gamida Cell and Be The Match BioTherapies® Announce Strategic Collaboration

Gamida Cell Announces 2019 Goals and Provides Company Update

Gamida Cell Announces Publication of Phase 1/2 Clinical Data of NiCord® in the Journal of Clinical Oncology

Gamida Cell Reports Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at ASH 2018 Annual Meeting

Gamida Cell to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference

Gamida Cell Announces New Translational Data for Nicord® to Be Presented at ASH 2018 Annual Meeting

Gamida Cell Announces Pricing of Initial Public Offering

Gamida Cell Strengthens Its Board of Directors with Appointment of Robert Blum as Chairman

Gamida Cell Expands its Leadership Team with the Appointment of Jaren Madden as Vice President, Investor Relations and Corporate Communications

Gamida Cell Expands Leadership Team with Appointments of Tzvi Palash as Chief Operating Officer and John Schick as Vice President of Market Access

Gamida Cell Receives Orphan Drug Designation from the FDA for NiCord® as a Treatment for Hematopoietic Stem Cell Transplantation

Gamida Cell to Present Preliminary Data from Ongoing Phase I NAM-NK Study at AACR International Meeting on Advances in Malignant Lymphoma

Gamida Cell to Present NiCord® Data at ISCT 2018 Annual Meeting

Gamida Cell Strengthens Leadership Team with Appointments of Josh Hamermesh as Chief Business Officer and Paul Nee as Vice President of Marketing

Gamida Cell to Present Immune Reconstitution Data for its NiCord® Program at the 2018 EBMT Annual Meeting

Gamida Cell to Present at Upcoming Investor Conferences

Gamida Cell Appoints Shai Lankry as Chief Financial Officer

Gamida Cell to Present Data from NiCord® Programs at the 2018 BMT Tandem Meetings

Gamida Cell Announces Initiation of a Phase I Study of NAM-NK Cells Immunotherapy Program for Non-Hodgkin Lymphoma and Multiple Myeloma

Gamida Cell Presents Data from Two Key Development Programs at the 2017 ASH Annual Meeting

Gamida Cell Appoints Julian Adams, Ph.D., Chairman and Chief Executive Officer

Gamida Cell to Present New Data from Key Programs at 2017 ASH Annual Meeting

Gamida Cell World Cord Blood Day Conference, November 15, 2017

Gamida Cell Announces First Patient Transplanted in Phase 1/2 Study of CordIn for Severe Aplastic Anemia and Hypoplastic MDS

Gamida Cell Inc. Names Ronit Simantov, M.D. as Chief Medical Officer

Gamida Cell Announces $40 Million Private Financing

Gamida Cell Appoints Nobel Prize Laureate Professor Roger Kornberg and Immune Oncology Expert Dr. Michael Perry to its Board of Directors

Gamida Cell Announces Publication of Positive Clinical Outcomes from NiCord-Transplanted Patients in the Journal of Biology of Blood and Marrow Transplantation

Gamida Cell Receives Additional EMA Orphan Drug Designation for NiCord® in Haematopoietic Stem Cell Transplantation (HSCT)

Gamida Cell Announces First Patient Transplanted in Phase 3 Registration Study of NiCord for Blood Cancers

Gamida Cell Presents Positive Data From Phase 1/2 Study of NiCord® as a Curative Treatment for Sickle Cell Disease at ASH 2016

Gamida Cell Names Julian Adams, Ph.D. New Chairman of the Board

Gamida Cell Receives FDA Breakthrough Therapy Designation For NiCord®

Gamida Cell Announces Appointment of Julian Adams, Ph.D.and Kenneth I. Moch to its Board of Directors

Gamida Cell Announces First Patient with Sickle Cell Disease Transplanted in Phase 1/2 Study of CordIn™ as the Sole Graft Source

Gamida Cell Presents Data From Phase 1/2 Study of NiCord® for High Risk Hematological Malignancies at ASCO 2016

Gamida Cell Announces $4.4 Million Grant from the Israeli Government

Gamida Cell Presents Additional Positive Data of NiCord® in Blood Cancer Patients at EBMT 2016

Patient focus

The needs and experiences of patients are at the core of everything we do. Read about one woman’s personal journey through cancer diagnosis and treatment.

Meet Stacey

Mission-driven science

We are developing a pipeline of potentially curative cell therapies, with our lead program in late-stage development.

Learn more

Dedicated team

We combine deep scientific experience with a passion for changing the lives of patients.

Meet us

Inspired to Cure

Pioneering new standards of care for patients with blood cancers and serious blood diseases

Latest News

Dec 09, 2019

Gamida Cell Announces Results from Phase 1 Study of GDA-201 and New Mechanism of Action Data at ASH 2019 Annual Meeting

Nov 21, 2019

Gamida Cell to Present at the 31st Annual Piper Jaffray Healthcare Conference

Nov 13, 2019

Gamida Cell Reports Third Quarter 2019 Financial Results and Provides Company Update

Nov 06, 2019

Gamida Cell Announces Data to be Presented at ASH 2019 Annual Meeting

Nov 05, 2019

Gamida Cell Announces the Date of Its Third Quarter 2019 Financial Results and Webcast

Sep 11, 2019

Gamida Cell and the CIBMTR Announce Collaboration to Advance Research for Life-Saving Cellular Therapy

Aug 06, 2019

Gamida Cell Reports Second Quarter 2019 Financial Results and Provides Company Update

Jul 23, 2019

Gamida Cell Announces the Date of Its Second Quarter 2019 Financial Results and Webcast

Jul 08, 2019

Gamida Cell Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

Jun 26, 2019

Gamida Cell Announces Pricing of $35 Million Public Offering of Ordinary Shares

Jun 24, 2019

Gamida Cell Announces Launch of Proposed Public Offering of Ordinary Shares

Jun 19, 2019

Gamida Cell and Lonza Establish Commercial Manufacturing Agreement for Omidubicel

Jun 05, 2019

Gamida Cell Bolsters Management Team with Appointment of Tracey Lodie, Ph.D., as Chief Scientific Officer

May 31, 2019

Gamida Cell Announces Data for Omidubicel Presented at the International Society for Cellular and Gene Therapy 2019 Annual Meeting

May 29, 2019

Gamida Cell to Hold Annual Meeting of Stockholders

May 09, 2019

Gamida Cell to Participate in Two Upcoming Healthcare Conferences in New York City

May 07, 2019

Gamida Cell Reports First Quarter 2019 Financial Results and Provides Company Update

Apr 30, 2019

Gamida Cell Announces the Date of Its First Quarter 2019 Financial Results and Webcast

Apr 22, 2019

Gamida Cell to Present at the Solebury Trout Class of 2018 Biotech IPOs Investor Day

Apr 05, 2019

Gamida Cell to Present at the 18th Annual Needham Healthcare Conference

Mar 21, 2019

Gamida Cell Nominates Two Healthcare Industry Veterans to Its Board of Directors

Feb 25, 2019

Gamida Cell Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update

Feb 23, 2019

Gamida Cell Announces Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at 2019 TCT Annual Meeting

Feb 21, 2019

Gamida Cell Presents New Data from Ongoing Phase 1 Study of NAM-NK and Initial Data from Phase 1/2 Study of NiCord® in Severe Aplastic Anemia at 2019 TCT Annual Meeting

Feb 19, 2019

Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells

Feb 14, 2019

Gamida Cell to Host Conference Call and Webcast to Review Data from NAM-NK and NiCord® Programs Being Presented at 2019 TCT Annual Meeting

Jan 24, 2019

Gamida Cell Announces Data from NAM-NK and NiCord® Programs to Be Presented at 2019 TCT Annual Meeting

Jan 22, 2019

Gamida Cell and Be The Match BioTherapies® Announce Strategic Collaboration

Jan 07, 2019

Gamida Cell Announces 2019 Goals and Provides Company Update

Dec 04, 2018

Gamida Cell Announces Publication of Phase 1/2 Clinical Data of NiCord® in the Journal of Clinical Oncology

Dec 03, 2018

Gamida Cell Reports Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at ASH 2018 Annual Meeting

Nov 28, 2018

Gamida Cell to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference

Nov 01, 2018

Gamida Cell Announces New Translational Data for Nicord® to Be Presented at ASH 2018 Annual Meeting

Oct 26, 2018

Gamida Cell Announces Pricing of Initial Public Offering

Sep 18, 2018

Gamida Cell Strengthens Its Board of Directors with Appointment of Robert Blum as Chairman

Aug 06, 2018

Gamida Cell Expands its Leadership Team with the Appointment of Jaren Madden as Vice President, Investor Relations and Corporate Communications

Jul 23, 2018

Gamida Cell Expands Leadership Team with Appointments of Tzvi Palash as Chief Operating Officer and John Schick as Vice President of Market Access

Jul 17, 2018

Gamida Cell Receives Orphan Drug Designation from the FDA for NiCord® as a Treatment for Hematopoietic Stem Cell Transplantation

Jun 18, 2018